Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC
September 15th 2015James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.
Read More